Meeting Overview | We are pleased to invite you to our Official EBCC-8 Sponsored Satellite Symposium, titled Metastatic Breast Cancer: Differentiation Drives Improved Outcomes in HER2-Negative Disease, on 21 March 2012 in Vienna, Austria. |
Date and Location | 21 March 2012
18.45-20.15
Hall GH
Austria Center Vienna
Bruno-Kreisky-Platz 1 A
A-1220 Vienna, Austria |
Faculty | Chair
José Baselga, MD, PhD
Massachusetts General Hospital
Boston, Massachusetts, United States
Faculty
Thomas Bachelot, MD
Centre Léon Bérard
Lyon, France
Alessandra Gennari, MD, PhD
Galliera Hospital
Genoa, Italy
Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany |
Agenda |
| |
|
Welcome and introduction
José Baselga, MD, PhD
|
| 18.45 |
|
Heterogeneity: A hallmark of both the disease and its treatments
Nadia Harbeck, MD, PhD
|
| 19.00 |
|
Selected clinical trials for HER2-negative metastatic breast cancer: Where's the beef?
|
| |
|
Tyrosine kinase inhibition (15 min)
José Baselga, MD, PhD
|
| |
|
Nab technology platform-based chemotherapy: How is it different? (15 min)
Alessandra Gennari, MD, PhD
|
| |
|
mTOR inhibition + endocrine therapy (15 min)
Thomas Bachelot, MD
|
19.45
|
|
Applying the data: From clinical trials to the clinic
All faculty
|
| 20.10 |
|
Concluding remarks
José Baselga, MD, PhD
|
|
Target Audience | This educational activity is specifically designed for medical oncologists, surgical and radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with metastatic breast cancer. |
Learning Objectives | After successful completion of this educational activity, participants should be able to:
- Discuss the implications of heterogeneity within HER2-negative breast cancers on clinical behavior and treatment selection
- Examine recent clinical trial data on the efficacy and safety of therapy for HER2-negative breast cancer, including endocrine therapy, chemotherapy, and targeted agents
- Discuss strategies to integrate emerging clinical trial data into current standards of care for patients with HER2-negative breast cancer
|
|
|
|
Organizer | This meeting is a prIME Oncology activity.
|
Support | This activity is supported by educational grants from:
|
|
